MSH Capital Advisors LLC Invests $589,000 in IQVIA Holdings Inc. $IQV

MSH Capital Advisors LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,050 shares of the medical research company’s stock, valued at approximately $589,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in IQVIA during the 2nd quarter valued at $2,811,292,000. Boston Partners purchased a new position in shares of IQVIA in the third quarter worth $676,698,000. Norges Bank purchased a new stake in shares of IQVIA during the fourth quarter valued at $497,445,000. Victory Capital Management Inc. increased its holdings in IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after buying an additional 1,614,063 shares in the last quarter. Finally, Orbis Allan Gray Ltd increased its holdings in IQVIA by 96.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after buying an additional 933,554 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a report on Thursday, July 9th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. HSBC reiterated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. Robert W. Baird raised their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, Barclays reiterated an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Trading Up 4.0%

Shares of IQVIA stock opened at $249.62 on Thursday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $251.36. The company’s fifty day simple moving average is $210.23 and its 200-day simple moving average is $186.82. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $41.09 billion, a PE ratio of 30.97, a P/E/G ratio of 2.04 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has authorized a share repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last 90 days. Corporate insiders own 1.70% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.